Abstract:
Tumor profiling studies aim to determine gene expression signatures that can discriminate between
different sub-types of tumors. We have recently discovered a signature that can reliably detect
which primary head-neck tumors have metastasized to local lymph nodes. This signature has great
potential for clinical application and also offers unique insights into how metastasis occurs. Despite
these obvious advances, discussed here alongside several other findings, such tumor profiling
studies are currently receiving harsh criticism. We make clear that such evaluations can themselves
also be critically evaluated. The separation between the two factions actually shows that it is too
early to either dismiss of exalt tumor profiling studies. Final judgment requires waiting for the
results of larger prospective studies carried out in parallel with current clinical practice.